Iconovo releases Q2-2024 report

“A quarter of intense business development and constructive negotiations.” says Johan Wäborg, CEO at Iconovo.

CEO MESSAGES: 

STRATEGIC INITIATIVES IN THE SECOND QUARTER OF THE YEAR

INTENSE STAGE IN THE LICENSING PROCESS FOR ICOPRE®

FIRST STEP IN ICONOVO’S NEW OBESITY TREATMENT INITIATIVE

PROJECT WITH ENA RESPIRATORY NOT EXTENDED

PROJECT SUCCESSES WITH AFFILOGIC PRESENTED AT RDD

NEW PATENT FOR ICORES® IN CHINA STRENGTHENS COMPETITIVE PROTECTION

WE ARE FOLLOWING OUR PLAN TO ACHIEVE PROFITABILITY

To read the full report, follow the link